METTL14-DT

Across TCGA pan-cancer cohorts, METTL14-DT RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of METTL14-DT’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where METTL14-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types METTL14-DT is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, CHOL, and PAAD are the cancer types where METTL14-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in METTL14-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.027	.001	4	view →
CHOL	All	All	+0.173	<.001	3	view →
PAAD	Male	All	+0.140	.002	2	view →
THCA	All	All	−0.128	.017	2	view →
LUSC	All	All	+0.051	.012	2	view →
LUAD	All	IV	+0.050	.037	2	view →
KIRC	Female	All	−0.071	.015	1	view →
STAD	Male	All	+0.067	.035	1	view →
COAD	All	All	+0.030	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

METTL14-DT–LIHC

Open the LIHC breakdown →